SOSV is a global venture capital firm that provides early-stage and seed investments alongside structured accelerator programs and deeply resourced facilities to accelerate product development. Focused on deep tech, human and planetary health, and cross-border software, SOSV backs startups from pre-seed onward and runs programs that accelerate technical development, regulatory strategy, and fundraising. The firm maintains labs and engineering spaces with specialist staff in multiple regions, including the United States and Asia, to support portfolio companies in biosafety, chemistry, mechatronics, analytics, and electrical engineering. Programs such as HAX and other live events offer founders access to prototyping, testing, and investor networks. Annually, SOSV makes around sixty pre-seed investments (up to roughly $550k each) and participates in numerous follow-on rounds, leveraging a global portfolio and extensive co-investor network to help deeply technical startups scale and reach markets.

The European Innovation Council is a Brussels-based European Union organization established in 2018 to support deep‑tech innovation by helping startups, researchers and technology transfer activities move ideas toward market. It operates a portfolio of programs including Pathfinder, Accelerator, Transition, STEP Scale Up and Pre-Accelerator, and collaborates with partners to provide funding, mentorship and resources across the innovation lifecycle. The council emphasizes high-impact, science‑driven technologies with broad societal benefit and promotes inclusion, with initiatives to involve women‑led projects. It engages the wider ecosystem through awards, events and community initiatives and monitors impact through data platforms. By coordinating with private investors and other stakeholders, it aims to accelerate the scale-up of European deep‑tech firms and strengthen Europe’s position in global technology leadership.

Qiming Venture Partners is a global venture capital firm founded in 2006 with offices in Shanghai, Beijing, Suzhou, Hong Kong, and Singapore. It manages multiple funds and more than $9.5 billion in committed capital, investing across healthcare, information technology, new consumer patterns, mobile internet, AI, robotics, and related sectors. The firm backs early to growth-stage companies, including numerous healthcare, tech and consumer businesses, and has built a broad portfolio exceeding several hundred companies with a substantial track record of exits, including IPOs and M&A. It operates a U.S. presence to back cross-border opportunities and emphasizes a hands-on approach, leveraging industry resources and an extensive network to support portfolio companies through strategic decisions, governance, and scaling. The portfolio spans marquee names and innovative startups, reflecting a focus on accelerating China's innovation and delivering long-term value for entrepreneurs and stakeholders.

OrbiMed is a global healthcare-focused investment firm founded in 1989 and headquartered in New York. It manages assets across public and private markets and pursues opportunities across the healthcare spectrum, including biopharmaceuticals, medical devices, diagnostics, digital health, and health services. The firm invests in startups, growth-stage companies, and established entities, leveraging scientific and medical expertise to support development and commercialization. It also offers financing solutions such as structured debt and royalty monetization for intellectual property and medical diagnostics.

High-Tech Gründerfonds is a Germany-based venture capital firm established in 2005 that funds early-stage technology startups in Germany. Based in Bonn with an office in Berlin, it supports companies across software, information technology, digital and industrial tech, life sciences, chemistry, IoT, energy, and related fields by providing initial capital and subsequent funding, complemented by active guidance from investment managers. The firm typically acts as a lead investor and cooperates with other investors to help portfolio companies advance from concept to market, with a focus on startups that have begun commercial operations. By combining financing with hands-on support, HTGF aims to help high-potential founders develop their technology, validate products, and scale within the German market.

Alumni Ventures is a venture capital firm based in Manchester, New Hampshire, with offices in New York, Boston, Menlo Park, Chicago, London, and Tokyo. It enables accredited investors, especially alumni networks, to access diversified venture opportunities by co-investing alongside leading venture capital firms. Through funds, syndicates, and investing clubs, it sources opportunities across stages and geographies, conducts rigorous due diligence, and aims for transparent, founder-friendly support. The firm backs a diversified portfolio of startups, including more than 1,600 companies, and has attracted substantial committed capital and a large community of individual investors, underscoring its mission to democratize access to venture capital while partnering with established VC firms.

Ben Franklin Technology Partners of Southeastern Pennsylvania is a nonprofit organization founded in 1982 that supports the technology ecosystem in Southeastern Pennsylvania by providing capital, guidance, and connections to early-stage technology companies. It acts as a seed-stage capital provider for the region's technology sectors, facilitates university-industry partnerships to accelerate commercialization, and undertakes initiatives to strengthen the entrepreneurial community across Philadelphia and surrounding counties, with a focus on creating jobs and fostering regional innovation.

Khosla Ventures is a California-based venture capital firm founded in 2004 that provides capital and strategic support to technology-driven startups across early- to late-stage cycles. It pursues opportunities in AI, digital health, healthcare technologies, sustainability, fintech, consumer and enterprise technology, and other frontier areas, focusing on innovative business models and world-class teams. The firm emphasizes a contrarian, long-term approach and seeks to help entrepreneurs address meaningful societal and economic challenges through science, technology, and design.

Legend Capital is a Beijing-based venture capital firm and subsidiary of Legend Holdings, focused on backing high-growth Chinese technology and related companies. Since its inception in 2001, it has managed multiple funds totaling up to approximately US$700 million, investing primarily in early-stage IT ventures with operations centered in China or markets related to China. The firm targets sectors including network applications and services, outsourcing and professional services, and infrastructure such as IC design and key components, as well as mid-market growth companies in consumer goods, clean technology, healthcare, equipment manufacturing, and modern services. Legend Capital actively supports portfolio companies with resources for business development and market execution in China to create value and maximize returns. Notable portfolio companies have included Joyo.com, SinoCom, Solarfun Power, Spreadtrum Communications, China Sunshine Paper, VanceInfo, and Eyang. Legend Capital operates as a Beijing-based venture capital investor with a broad focus on technology-enabled sectors and China-linked opportunities.

European Investment Bank is a key financial institution of the European Union that finances projects across Europe and beyond to promote sustainable development. It focuses on climate action, innovation, regional development, and infrastructure, providing financing through loans, guarantees, and advisory services to public and private sectors; supports large-scale infrastructure, technology development, and access to capital for enterprises; aligns with EU priorities such as the European Green Deal and digital transformation, including initiatives like InvestEU and Ukraine's recovery. It operates globally with a significant presence in the EU and neighboring regions, aiming to boost growth, create jobs, and improve living standards, while upholding transparency, accountability, and stakeholder engagement.

BioVenture, established in September 2013, specializes in early-stage venture capital investments in the field of life sciences, focusing on biotechnology, drug discovery, medical devices, and healthcare services companies. With a fund size of 540 million yuan, BioVenture provides capital and post-investment support to innovative companies with high growth potential. Backed by Suzhou Industrial Park and BioBay, BioVenture aims to become one of China's most successful medical and pharmaceutical venture funds by leveraging its industry expertise and resources. The team at BioVenture consists of senior investment professionals with deep knowledge of domestic and foreign markets, aiming to help companies grow rapidly and achieve greater success while delivering considerable returns to fund investors. Through joint venture development cooperation, BioVenture seeks to drive innovation and growth in the medical and pharmaceutical industry.

Deerfield Management is a New York City–based healthcare investment and information platform that advances health outcomes through flexible funding, data-driven insights, and philanthropic support. The firm invests in and builds healthcare companies across biotechnology, pharmaceuticals, diagnostics, medical devices, healthcare services, and digital health, leveraging a dedicated research and development engine, Deerfield Discovery and Development, and in-house facilities that support scientific collaboration and discovery. Its Intelligence offering uses AI, data and market research to drive technology and strategy across its portfolio and the broader healthcare ecosystem. Deerfield operates the Cure hub housing portfolio companies and modern labs, and has partnered with organizations such as Blue Cross Blue Shield of North Carolina to develop services like Alo that assist independent physicians in managing the business of medicine. The Deerfield Foundation funds education, healthcare access and health outcomes initiatives, reflecting a broader philanthropic approach to accelerating medical innovation through partnerships and strategic collaborations.

HealthTech Capital is an angel investor group focused on health technology and medical technology startups. Founded in 2010 and based in Los Altos Hills, California, it accelerates healthcare innovation by connecting healthtech startups with accredited angel investors, healthcare systems, venture capitalists, and corporate investors. The organization provides investment and customized mentoring programs, facilitating early-stage funding and ongoing collaboration across clinical providers, venture and corporate partners. It aims to create an ecosystem that includes leading clinical providers, venture firms, and strategic industry players, and has supported portfolio companies with over one billion dollars in follow-on capital. Its membership spans entrepreneurs, clinicians, executives, venture capitalists, and corporate investors nationwide, emphasizing market collaboration and opportunities for early-stage innovation.

New Enterprise Associates is a United States-based venture capital firm founded in 1977 and headquartered in Menlo Park, California. It invests in technology and healthcare companies across multiple stages, from seed to growth and IPO, and provides strategic support in product development and market expansion. The firm targets sectors including software, AI, consumer technology, digital health, life sciences, and energy technology, and pursues opportunities worldwide. NEA emphasizes long-term partnerships with founders, drawing on domain expertise and a broad network to help portfolio companies scale. It maintains a diverse portfolio across the United States, Asia and other regions, reflecting a global approach to venture investing.

Gilde Healthcare is a specialist investment firm focused on the healthcare sector, headquartered in Utrecht, Netherlands, with a transatlantic footprint in Europe and North America. It pursues venture, growth and private equity opportunities in areas such as medtech, pharmaceuticals, life sciences, diagnostics, digital health, and healthcare services, backing companies at various stages and supporting them with strategic guidance, regulatory progress, and market expansion.

Eli Lilly and Company is a global pharmaceutical company focused on discovering, developing, manufacturing, and marketing medicines across neuroscience, cardiometabolic, cancer, and immunology areas. It operates manufacturing and distribution facilities in the United States, Puerto Rico, and about 25 other countries, with products sold in roughly 135 countries. The company emphasizes ongoing research to create therapies that address unmet medical needs and to improve patient outcomes. Its portfolio spans treatments for diabetes and metabolic conditions, cancer, autoimmune diseases, and other serious conditions.

RA Capital Management is a Boston-based investment firm focused on healthcare, life sciences, and planetary health, investing in public and private companies across stages from seed to late-stage financings. The firm emphasizes evidence-based, science-led investing guided by internal research capabilities, including TechAtlas. It operates Raven, a biomedical innovation incubator that supports entrepreneurs and developers, and pursues value creation through collaborative partnerships, often co-investing and taking board positions. With a multidisciplinary, data-driven approach, RA Capital seeks to back management teams from inception through commercialization and beyond, aiming to improve patient outcomes and advance medical innovation.

Arboretum Ventures is a Michigan-based venture capital firm founded in 2002 and headquartered in Ann Arbor. It targets healthcare companies at seed through growth stages across the United States, with a focus on the Midwest and Michigan. The firm invests primarily in healthcare services, medical devices, diagnostics, healthcare information technology, therapeutics, life science tools, and other tech-enabled healthcare sectors, typically committing between $5 million and $15 million per company.

SFC Capital is a venture capital firm in the United Kingdom that focuses on early-stage investments, including pre-seed and seed rounds, mainly within the UK. Founded in 2012, it backs a broad range of sectors such as software, technology, e-commerce, consumer, enterprise software, fintech, digital health, food technology, and mobile. The firm combines an angel network with seed funds to provide capital and strategic support to British startups, offering access to SEIS- and EIS-qualifying opportunities and hands-on guidance to help portfolio companies scale.

Keiretsu Forum is a global invitation-only network of accredited private equity investors, angel investors and corporate or institutional financiers, organized to connect capital with growth-focused companies. Through chapters worldwide, it links entrepreneurs with capital and strategic resources, hosting selective presentations to generate deal flow and investment opportunities. Members join by invitation and review opportunities collectively but make individual investment decisions, enabling collaboration while preserving autonomy. Keiretsu Forum emphasizes rigorous due diligence and a disciplined screening process, with activity across sectors such as technology, healthcare and life sciences, clean tech, consumer products and real estate. By pooling capital and expertise, it aims to support high-growth companies and foster mutually beneficial partnerships across markets.

Novo Nordisk is a global pharmaceutical company headquartered in Denmark that discovers, develops, manufactures, and markets medicines primarily for diabetes care and related chronic diseases. Its portfolio includes insulin therapies and other diabetes treatments, with a growing focus on obesity management, growth disorders, haemophilia, and cardiovascular conditions. The company emphasizes research and development to advance innovative therapies, including metabolic and cardiometabolic medicines, and aims to expand access to essential medicines worldwide. Novo Nordisk places a strong emphasis on patient safety, sustainability, governance, and transparent reporting, reflecting responsible business practices and ESG commitments. Operating globally, it pursues collaborations and partnerships to address global health needs and strives to improve health outcomes through scientific excellence and responsible stewardship of resources.

IDG Capital is a global investment firm with over 30 years of experience, originating in China and headquartered in Hong Kong. It finances companies across venture capital, growth equity, buyouts, secondary markets and public markets, supporting a lifecycle from early stage to scale. The firm maintains a worldwide presence with offices across the Americas, Europe and Asia Pacific, and backs a large portfolio through long-term, value-driven partnerships with founders. IDG Capital leverages a combination of local market insight and global resources to identify inbound and outbound opportunities in China and other Asian markets, while collaborating with sovereign wealth funds, pension funds, and other institutional investors as limited partners. Its track record includes hundreds of exits and involvement in notable growth stories across technology, consumer, healthcare and other sectors, reflecting a disciplined approach to building lasting companies.

MassVentures is a Massachusetts-based venture capital firm established in 1978 as a quasi-public entity to support seed and early-stage startups in the Commonwealth's innovation economy. It funds high-growth ventures from concept to commercialization and focuses on deep tech areas such as quantum computing, clean energy, AI, and biotech, alongside information technology, healthcare, cybersecurity, e-commerce, mobile, manufacturing, and robotics. The organization is governed by an independent board and backed by experienced investment professionals, and it provides funding, mentorship, strategic guidance, and non-dilutive grants through programs including MV Capital, MV Accelerate, and MV Spinouts, often in collaboration with academic institutions. MassVentures has funded more than 190 companies and has played a key role in expanding Massachusetts' innovation ecosystem by building inclusive teams and connecting founders with capital and expertise.

U.S. Venture Partners is a Menlo Park, California-based venture capital firm that backs early-stage technology and healthcare companies. With more than thirty years of operation, it helps entrepreneurs transform ideas into growth companies, focusing on enterprise software, IT security, consumer internet, mobile, e-commerce, and IT-enabled healthcare services. The firm targets startups in information technology and healthcare that can scale in the United States, and in some cases Israel, and it emphasizes collaboration with teams that include former entrepreneurs, technologists, executives, and industry experts. USVP invests in software, healthcare, cybersecurity, and related technology-enabled sectors, supporting portfolio companies through early development and scale-up.

Shenzhen Capital Group is a government-backed venture capital firm founded in 1999 and based in Shenzhen, China. It concentrates on SMEs and innovative high-tech enterprises in emerging industries, including IT, internet, new media, biopharma, new energy, environmental protection, new materials, chemical engineering, and high-end equipment manufacturing, supporting companies in the start-up, growth and transformation stages. The group pursues a long-term, ESG-conscious investment approach and leverages a dense funding network to connect government, industry and academia, promoting regional innovation from the Guangdong-Hong Kong-Macao Greater Bay Area to inland corridors. Its portfolio spans leading Chinese technology and manufacturing firms, reflecting a broad footprint across semiconductors, healthcare, energy and industrial tech, with assets under management of about 339 billion RMB.

IP Group is a global investment company that backs science- and technology-based ventures by commercialising intellectual property generated at research-intensive institutions. It manages the entire process from identifying suitable IP to developing companies or forming commercial partnerships, leveraging deep industry and financial insight to accelerate value creation for portfolio companies, partners, and investors. The firm concentrates on healthtech, deeptech, and cleantech sectors, providing capital, strategic guidance, and operational support to help translate scientific innovations into scalable businesses. IP Group collaborates with universities, superannuation funds, and corporations to build world-class companies and deploy capital across early-stage and growth opportunities. Notable initiatives include the Climate Catalyst Fund, launched with CEFC to scale decarbonisation technologies, reflecting a track record of pursuing sustainable impact alongside financial return.

Innovation Works is a Pittsburgh-based venture capital firm and regional technology-support organization that funds seed-stage technology companies in Southwestern Pennsylvania. It provides capital, mentorship, and programmatic resources to startups in robotics, hardware, software, and life sciences, and operates accelerators and programs such as AlphaLab, the Robotics Factory, the Seed Fund, and Manufacturing Assistance to advance prototypes to production. As the Ben Franklin Technology Partner for Southwestern Pennsylvania, supported by the Pennsylvania Department of Community and Economic Development, it connects founders with capital, expertise, and a broad regional network to help companies grow faster. Throughout its history, Innovation Works has nurtured hundreds of startups and aided portfolio firms in raising substantial follow-on funding and achieving exits, underscoring its role as a leading early-stage investor and ecosystem builder in the region.

SV Health Investors is a private equity and venture capital firm that focuses on healthcare and life sciences, including biotech, therapeutics, and medtech. Founded in 1993 as SV Life Sciences, the firm operates globally with offices in Boston, San Francisco, and London and maintains a long US and Europe track record. It funds companies across stages, partnering with entrepreneurs to build breakthrough treatments and technologies, and provides strategic guidance and industry expertise to help portfolio companies grow and pursue IPOs or strategic transactions. With a team of over 50 professionals, SV Health Investors emphasizes value creation across its healthcare investments and seeks to transform healthcare through its portfolio.

Gaingels is a venture investment syndicate focused on supporting LGBTQ founders and inclusive leadership by investing across stages and partnering with other venture firms to back diverse, high-potential companies. It maintains a global portfolio of 130+ companies and has deployed tens of millions in capital to date. The organization actively helps portfolio companies identify and recruit diverse talent for C-suite and board roles and cultivates a worldwide network of investors, operators, and entrepreneurs who share a commitment to positive social change through business.

Kurma Partners is a Paris-based investment firm specializing in financing innovation in healthcare and biotechnology across Europe, from early development to growth-stage capital. Founded in 2009, it operates as a private equity and venture capital firm dedicated to funding therapeutic and medical innovations, and it maintains close collaboration with European academic researchers, hospitals, and institutes to translate scientific advances into medicines and medical devices. The firm supports portfolio companies through capital and strategic guidance, investing across healthcare, life sciences, digital health, and related technologies, and it maintains a network of partnerships to advance translational science, with a focus on sustainable development and ESG practices.

Sofinnova Partners is an independent venture capital firm based in Paris, France, focused on life sciences. It invests in startups from seed to later stages in biopharmaceuticals, biotech, medical devices, industrial biotechnology, and related healthcare technologies. The firm often takes lead or cornerstone roles in rounds, sits on boards, and provides active support from formation onward to help entrepreneurs develop transformative innovations. It also considers corporate spin-offs and occasional turnaround opportunities, with the aim of delivering meaningful health advances alongside attractive returns for investors.

Mitsubishi UFJ Capital is a Tokyo-based venture capital firm established in 1974 that funds seed, development-stage and startup companies in Japan, focusing on life sciences, healthcare, biotechnology, information technology, electronics and other high-technology sectors such as fintech and AI. It pursues cross-border opportunities and investment syndication, often collaborating with MUFG and international partners to support portfolio companies’ growth and access to overseas markets, and to connect Japanese portfolio companies with strategic partners and potential exits.

Parkwalk Advisors is a London-based venture capital firm focused on investing in UK university spinouts and other research-intensive technology companies across sectors such as artificial intelligence, big data, life sciences, cleantech, materials, medical technology, quantum computing and the future of mobility. The firm targets early- to growth-stage opportunities and typically engages in seed to growth capital rounds, prioritizing UK-based companies originating from university research. Parkwalk leverages academic networks, technology transfer offices and venture ecosystems to access high-quality deal-flow and supports portfolio companies through development toward scale. Founded in 2009, Parkwalk operates in connection with IP Group, a university IP commercialisation company.

Mayo Clinic is a nonprofit medical practice, research, and education organization based in Rochester, Minnesota, with campuses in Arizona, Florida, and abroad. Founded in the 19th century, it provides comprehensive medical care across a wide range of specialties, supports medical education in clinical medicine and biomedical sciences, and conducts extensive biomedical research. The organization emphasizes patient-centered care, clinical excellence, and collaboration among physicians, scientists, and educators. Mayo Clinic also operates Mayo Clinic Platform, an initiative that builds a data- and AI-enabled ecosystem to connect clinical data, developers, and providers, supporting research, digital health tools, and innovation through partnerships with health tech companies and academic institutions. Mayo Clinic Ventures, the corporate venture arm, funds and translates inventions and discoveries into patient care. As a nonprofit enterprise, Mayo Clinic relies on philanthropy and diversified funding to advance care, education, and research while pursuing global collaborations and international programs.

Ontario Centre of Innovation is a provincial organization in Ontario funded by the Ministry of Economic Development, Job Creation and Trade that supports innovation and economic growth by transforming research into market-ready technologies. It facilitates collaboration between academia and industry to commercialize research and develop new technologies through programs such as Collaborate 2 Commercialize, Ready 4 Market, the Ontario Vehicle Innovation Network, and the Life Sciences Innovation Fund. OCI supports a broad range of sectors including life sciences, automotive, digital technologies, energy, environment and more, with the aim of attracting private investment, creating jobs, and strengthening Ontario’s global competitiveness. By leveraging Ontario’s postsecondary ecosystem, OCI translates research outcomes into commercial applications and promotes Made-in-Ontario innovations across the province, including digital transformation for small and mid-sized enterprises through digital competence initiatives.

Innova Memphis is a Tennessee-based venture capital firm founded in 2007 by the Memphis Bioworks Foundation. It focuses on pre-seed, seed and early-stage investments in biosciences, technology, and agri-tech companies located in Tennessee. The firm provides capital and support to help startups develop and scale, including assistance in connecting with potential licensees, strategic partners, and opportunities for follow-on investments or acquisitions. By backing innovative ventures with strong technical capabilities, Innova Memphis aims to accelerate product development, market entry, and economic growth within the state.

Versant Ventures is a healthcare-focused venture capital firm founded in 1999 and headquartered in San Francisco. It invests across the healthcare sector, including life sciences, biotechnology, pharmaceuticals, and medical devices, at all stages with an emphasis on discovery and development of novel therapeutics. The firm operates globally with offices in Canada, the United States, and Europe, delivering hands-on support to portfolio companies through in-house scientific and operating expertise. Versant pursues collaborative partnerships with entrepreneurs to translate research into clinical and commercial success and has a track record of portfolio companies achieving successful acquisitions or IPOs. The firm is registered as an investment adviser.

CD Capital is a Shanghai-based venture capital firm focused on medical technology and life sciences. Founded in 2013, it manages USD and RMB funds and supports a broad portfolio of companies across the medical technology and life sciences landscape, with a global network that helps identify opportunities in China's healthcare sector and beyond. The firm emphasizes rigorous investment selection, deep industry expertise, and a commitment to growing best-in-class companies and delivering solid returns to its investors.

ShangBay Capital is a Palo Alto‑based venture capital firm, founded in 2015, focused on early‑stage investments in healthcare technology. The firm backs companies operating in life sciences, medical devices, biotechnology, and mobile health, across the United States, and emphasizes disruptive healthcare innovation. With a team that collaborates closely with founders, ShangBay Capital seeks to address unmet clinical needs, navigate regulatory pathways, and pursue strategic exits to generate substantial value. It maintains active involvement in portfolio companies through expertise in global market opportunities, valuation, and growth acceleration, aiming to deliver strong returns for investors.

Ally Bridge Group is a private investment firm focused on healthcare and life sciences, with offices in New York and Hong Kong. Founded in 2013, it pursues venture, growth, private equity, and public equity investments across private and public markets in the United States, China, and Europe, targeting innovative drugs, medical devices, diagnostics, and digital health platforms. The firm combines scientific and clinical insight with capital markets expertise to bridge healthcare innovations with global markets, aiming to generate superior risk-adjusted returns while supporting portfolio companies through development and scale.

Hatteras Venture Partners is a North Carolina–based venture capital firm that invests in biotech, Medtech, diagnostics, healthtech, and related human medicine opportunities in the United States. It collaborates with founders to prioritize high‑quality science and teams with meaningful patient impact, providing extensive support beyond capital, including team recruitment, portfolio strategy, and regulatory planning. With a track record spanning more than 25 years and more than 100 companies built, Hatteras maintains a national investment footprint and a broad network of industry partners to create optionality and drive early‑stage growth while managing calculated risk. Founded in 2000, the firm focuses on early‑stage to growth opportunities across biopharmaceuticals, medical devices, diagnostics, and healthcare IT in the life sciences and healthcare sectors.

Sand Hill Angels is a Silicon Valley angel investor group based in Mountain View, California, comprised of experienced technology professionals who fund and mentor early-stage startups. With more than two decades in operation, the network focuses on seed to B-stage funding for disruptive, scalable technology companies and collaborates with venture capital funds and other angel networks to support portfolio companies. Members leverage an extensive network to connect entrepreneurs with customers, channels, and service providers, and provide real-time feedback and strategic guidance through programs such as Rapid Advice & Workshops. The group emphasizes patient capital and long-term commitment, seeking to foster thought leadership and ecosystem exposure through partnerships with curated organizations.

HighLight Capital is a venture capital firm based in Shanghai, China, focused on healthcare, life sciences, and wellness, including medical devices, pharmaceuticals, biotech, diagnostics, digital health, and consumer health products. It employs a value-oriented, research-driven approach aimed at long-term value creation, supported by proprietary industry research and operational enablement services to help portfolio companies grow in China’s health sector.

Lumira Ventures is a North American life sciences venture capital firm with offices in Toronto, Montreal, Vancouver and Boston. Founded in 1989, it partners with entrepreneurial management teams to build biotherapeutic, medical device, digital health and consumer health companies that address unmet needs and drive transformation. The firm focuses on biotechnology, biopharmaceuticals, medical devices, digital health and related sectors in Canada and the United States. It typically makes multi-million dollar investments and participates actively on boards to accelerate technology development, access follow-on funding, and foster strategic partnerships. Lumira Ventures has invested in more than 100 healthcare companies and maintains a portfolio of over 30 active investees across North America.

Panakes Partners is an independent venture capital firm based in Milan, Italy, that focuses on early-stage investments in life sciences and healthcare companies across Europe and Israel. It provides capital and hands-on support to entrepreneurs and scientific teams, leveraging a network of clinicians and industry experts to help portfolio companies advance products and reach clinical and commercial milestones. The firm’s activity spans dermatology, oncology, cardiovascular disease, and neurology, and it emphasizes sustainable impact through ESG principles and adherence to broader European innovation programs.

Peregrine Ventures is an Israeli venture capital firm focused on healthcare and life sciences. Based in Or Yehuda, it invests across the company lifecycle—from seed to growth—in areas including biotech, medical devices, digital health, and pharma. The firm aims to improve patients' quality of life by supporting portfolio companies with strategic guidance, business development, team building, and market access, drawing on deep industry knowledge and a multidisciplinary approach. Peregrine collaborates with entrepreneurs and industry stakeholders to help ventures scale and reach milestones, leveraging dedicated investment vehicles and an integrated, synergetic strategy to deliver value beyond capital. Its activities span global opportunities in the United States, Europe, and Israel, reflecting a long-standing track record in healthcare innovation.

Cenova Capital is a Shanghai-based venture capital firm specializing in late-stage and growth investments in China’s life sciences and healthcare sectors. Founded in 2010, it backs companies across pharmaceuticals, biotechnology, medical devices, diagnostics, healthcare services, and digital health, including health tech driven by artificial intelligence and big data. The firm has developed multiple funds to support early and expansion opportunities and has invested in a broad portfolio of healthcare services, medical products, and digital health ventures. Cenova targets opportunities that advance China’s healthcare system toward greater efficiency and market orientation, partnering with domestic and international institutional investors to support innovative companies at scale.

Almi Invest is a Swedish venture capital firm focused on early-stage startups, investing from pre-seed to Series A across technology, sustainability, industry, and life sciences. It operates as part of the Almi Group and is funded by the European Regional Development Fund, Almi AB, and regional partners. The firm provides not only capital but strategic guidance and access to an extensive investor network, supporting portfolio companies with growth and innovation. With a regional presence across Sweden and origins dating to 2009, Almi Invest backs startups that drive economic and environmental progress and work alongside other investors to accelerate development.

Trinity Capital is an independent provider of venture debt and equipment financing to venture-backed growth-stage companies in the United States. The company partners with venture capital firms, technology banks, and portfolio companies to deliver debt solutions that help startups scale while preserving equity. Its financing offerings include senior and subordinated term debt, asset-backed and equipment financings, sale-leasebacks, and revolving facilities, with optional refinancings and growth-oriented structures. Trinity Capital focuses on technology and other growth sectors, working with syndicate partners to support larger transactions when appropriate. Founded in 2008 and based in Arizona, the company operates nationwide through a client-centric, covenant-light approach and emphasizes customized structures designed to align with a company's growth trajectory.

Intuitive Surgical is a global healthcare company that develops, manufactures, and markets robotic-assisted minimally invasive surgery systems, led by the da Vinci Surgical System. The company offers the robotic platforms, associated instrumentation, disposable accessories, and warranty services to hospitals and surgical teams. Its systems support procedures across urology, gynecology, general surgery, and other specialties for adults and children under physician supervision. Since its deployment, more than 10,000 da Vinci systems have been installed in hospitals worldwide, with a substantial share in the United States and expanding presence in emerging markets. The business emphasizes training, support, and ongoing innovation to advance robotic-assisted care.